
Topic
Drug Pricing
WAC, ASP, NADAC, IRA negotiated prices, inflation rebates, and drug cost trends affecting access and coverage.

Pipeline· May 31, 2026 · 10 min read
By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence

Policy· May 30, 2026 · 11 min read
Medicare GLP-1 Bridge program guide for $50 obesity drug access
By Ran Chen#GLP-1#Medicare Part D#Drug Pricing

Pricing & Access· May 29, 2026 · 12 min read
Foundayo coverage guide: orforglipron access, pricing, and PA criteria
By Ran Chen#GLP-1#Obesity#Prior Authorization

Pricing & Access· May 22, 2026 · 15 min read
340B and IRA MFP non-duplication workflow for manufacturer teams

Pricing & Access· May 22, 2026 · 11 min read
Medicaid best-price risk in value-based drug contracts

Pricing & Access· May 22, 2026 · 12 min read
State PDAB launch-risk watchlist for market access teams
By Ran Chen#Drug Pricing#Market Access#Payer Policy